EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in prostate cancer
PDF | HTML | How to cite
Metrics: PDF 2881 views | HTML 3096 views | ?
Swathi Chinaranagari1, Pankaj Sharma1 and Jaideep Chaudhary1
1 Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA
Jaideep Chaudhary, email:
Keywords: ID4, EZH2, epigenetics, H3K27me3, prostate cancer
Received: June 07, 2014 Accepted: July 25, 2014 Published: July 25, 2014
Inhibitor of DNA binding/differentiation protein 4 (ID4) is dominant negative helix loop helix transcriptional regulator is epigenetically silenced due to promoter hyper-methylation in many cancers including prostate. However, the underlying mechanism involved in epigenetic silencing of ID4 is not known. Here, we demonstrate that ID4 promoter methylation is initiated by EZH2 dependent tri-methylation of histone 3 at lysine 27 (H3K27me3). ID4 expressing (LNCaP) and non-expressing (DU145 and C81) prostate cancer cell lines were used to investigate EZH2, H3K27me3 and DNMT1 enrichment on ID4 promoter by Chromatin immuno-precipitation (ChIP). Enrichment of EZH2, H3K27Me3 and DNMT1 in DU145 and C81 cell lines compared to ID4 expressing LNCaP cell line. Knockdown of EZH2 in DU145 cell line led to re-expression of ID4 and decrease in enrichment of EZH2, H3K27Me3 and DNMT1 demonstrating that ID4 is regulated in an EZH2 dependent manner. ChIP data on prostate cancer tissue specimens and cell lines suggested EZH2 occupancy and H3K27Me3 marks on the ID4 promoter. Collectively, our data indicate a PRC2 dependent mechanism in ID4 promoter silencing in prostate cancer through recruitment of EZH2 and a corresponding increase in H3K27Me3. Increased EZH2 but decreased ID4 expression in prostate cancer strongly supports this model.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.